×
About 128 results

ALLMedicine™ Lung Cancer Guidelines Center

Research & Reviews  26 results

European Respiratory Society Guideline on various aspects of quality in lung cancer care.
https://doi.org/10.1183/13993003.03201-2021
The European Respiratory Journal; Blum TG, Morgan RL et. al.

Nov 18th, 2022 - This ERS guideline is dedicated to the provision of good quality recommendations in lung cancer care. All the clinical recommendations contained were based on a comprehensive systematic review and evidence syntheses based on eight PICO questions. ...

Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLC
https://clinicaltrials.gov/ct2/show/NCT05400577

Aug 2nd, 2022 - There will be a two-part consent, including consent for KRAS testing and consent for treatment on trial. Testing for a KRAS G12C mutation in patients with resectable, stage Ib-IIIa NSCLC is currently not standard of care. Patients who are otherwis...

Impact of Delays in Lung Cancer Treatment on Survival.
https://doi.org/10.1016/j.chest.2021.08.051
Chest Zuniga PVS, Ost DE

Aug 24th, 2021 - Timely care is an important dimension of health care quality, but the impact of delays in care on lung cancer outcomes is unclear. Quantifying the impact of delays in cancer treatment on survival is necessary to inform resource allocation, quality...

Checkpoint inhibitors earn spot in new ESMO SCLC guidelines
https://www.mdedge.com/hematology-oncology/article/240233/lung-cancer/checkpoint-inhibitors-earn-spot-new-esmo-sclc
M. Alexander Otto

May 17th, 2021 - In new small cell lung cancer guidelines, the European Society of Medical Oncology calls for upfront atezolizumab or durvalumab in combination with four to six cycles of etoposide and a platinum for stage 4 disease. The strong recommendation is ba.

National lung cancer screening guidelines may miss younger African American individuals at high risk
https://www.mdedge.com/chestphysician/article/230226/lung-cancer/national-lung-cancer-screening-guidelines-may-miss-younger
Andrew D. Bowser, MDedge News

Oct 19th, 2020 - National guidelines failed to classify many younger African American lung cancer patients as being eligible for lung cancer screening in a recent retrospective study, the lead author reported at the annual meeting of the American College of Chest.

see more →

Guidelines  3 results

Treatment of tobacco use in lung cancer: Diagnosis and management of lung cancer, 3rd e...
https://doi.org/10.1378/chest.12-2349
Chest Leone FT, Evers-Casey S et. al.

May 10th, 2013 - Continued tobacco use in the setting of lung cancer management is frequently confounding and always of critical importance. We summarized the published literature concerning the management of tobacco dependence in patients with lung cancer and off...

Evaluation of individuals with pulmonary nodules: when is it lung cancer? Diagnosis and...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3749714
Chest Gould MK, Donington J et. al.

May 10th, 2013 - The objective of this article is to update previous evidence-based recommendations for evaluation and management of individuals with solid pulmonary nodules and to generate new recommendations for those with nonsolid nodules. We updated prior lite...

Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung canc...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694611
Chest Socinski MA, Evans T et. al.

May 10th, 2013 - Stage IV non-small cell lung cancer (NSCLC) is a treatable, but not curable, clinical entity in patients given the diagnosis at a time when their performance status (PS) remains good. A systematic literature review was performed to update the prev...

see more →

Clinicaltrials.gov  2 results

Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLC
https://clinicaltrials.gov/ct2/show/NCT05400577

Aug 2nd, 2022 - There will be a two-part consent, including consent for KRAS testing and consent for treatment on trial. Testing for a KRAS G12C mutation in patients with resectable, stage Ib-IIIa NSCLC is currently not standard of care. Patients who are otherwis...

Clinical Study of Combination Therapy With Ectiecinib, Pemetrexed and Platinum in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutations.
https://clinicaltrials.gov/ct2/show/NCT03992885

Jun 20th, 2019 - The positive rate of EGFR mutations in lung adenocarcinoma patients is about 50% in both Asian population and China.Domestic and international clinical studies have found that targeted therapy combination chemotherapy can prolong the overall survi...

see more →

News  20 results

Checkpoint inhibitors earn spot in new ESMO SCLC guidelines
https://www.mdedge.com/hematology-oncology/article/240233/lung-cancer/checkpoint-inhibitors-earn-spot-new-esmo-sclc
M. Alexander Otto

May 17th, 2021 - In new small cell lung cancer guidelines, the European Society of Medical Oncology calls for upfront atezolizumab or durvalumab in combination with four to six cycles of etoposide and a platinum for stage 4 disease. The strong recommendation is ba.

Bounty of Novel Drugs Ushers In New Era for ALK-Positive NSCLC
https://www.onclive.com/view/bounty-of-novel-drugs-ushers-in-new-era-for-alkpositive-nsclc

Dec 5th, 2020 - During the past decade, ALK inhibitors have followed a rapid trajectory from bench to bedside, taking over from chemotherapy as standard frontline treatment for patients with advanced non— small-cell lung cancer (NSCLC) with ALK gene rearrangement...

7 in 2011: A Short List of Drugs to Watch
https://www.onclive.com/view/7-in-2011-a-short-list-of-drugs-to-watch

Dec 5th, 2020 - From tiny biotech firms to giant pharmaceutical companies, the oncology drug development pipeline is pulsing with activity. There are nearly 900 potential new medicines and vaccines to treat cancer under study in the United States, according to th...

Reimbursement and Managed Care News for January 2008
https://www.onclive.com/view/articles_rcm_jan2008

Dec 5th, 2020 - Dosing Patterns and Costs of Erythropoesis-Stimulating Agents in Patients With Cancer A retrospective study of nearly 9,000 patients with cancer receiving epoetin alfa or darbepoetin alfa found that costs and dosing regimens varied conside...

High-risk Blacks Missed by Lung Cancer Screening Guidelines
https://www.staging.medscape.com/viewarticle/939437

Oct 20th, 2020 - National guidelines failed to classify many younger African-American lung cancer patients as being eligible for lung cancer screening in a recent retrospective study, the lead author reported at the annual meeting of the American College of Chest ...

see more →